Home » Newsletters » BioWorld Science

BioWorld Science

May 31, 2018

View Archived Issues

ConSynance announces initiation of toxicology studies of CSTI-300 for IBS-D

Kissei announces negative topline results from the additional phase III study of KPS-0373

Academia and industry establish immune-mediated inflammatory diseases consortium

Researchers from U.S. patent 5-HT1F receptor agonists

Japanese researchers divulge RDH10 inhibitors

U7-snRNA therapy targeting the DUX4 gene developed for facioscapulohumeral muscular dystrophy

Researchers develop early-metastatic RCC model in chickens

Zai Lab and Crescendo enter licensing agreement for antibody VH domain therapeutic

GSK, Cloud Pharmaceuticals form drug discovery collaboration

FDA approves Xeljanz for moderate to severely active ulcerative colitis

GlycoMimetics enters agreement with NCI for pivotal study of uproleselan in AML

FDA grants priority review to Fycompa pediatric sNDA

Arix, Evotec and Fred Hutchinson establish academic bridge collaboration

Denali Therapeutics exercises option to acquire F-star Gamma

Treeway completes phase I study of oral formulation of TW-001 for ALS

Natural killer cell phenotype GAIA-102 has antitumor activity

Phase II EQUATOR study of filgotinib in psoriatic arthritis meets primary endpoint

FDA places clinical hold on IND for CTX-001 in sickle cell disease

Five Prime collaborates with Roche on IHC companion diagnostic assays

Encouraging results seen with pegilodecakin plus pembrolizumab or nivolumab in NSCLC, RCC patients

Syndax and Nektar collaborate to study combination of NKTR-214 with entinostat in melanoma

FDA clears Janssen to begin phase Ib/II trial of JNJ-68284528 in multiple myeloma

Researchers describe potent antitumoral activity of KY-1055, a dual anti-ICOS/PD-L1 antibody